drugset / Trial / NCT01765192

Roflumilast Plus Montelukast in Adults With Severe Asthma

NCT01765192

Phase 2 Completed 64 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).

Timeline

Start
2013-02
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 500 ug Oral
Background Montelukast Other / unclassified 10 mg Oral

Indications